Orchestrating a Patient-Centric Cell/Gene Ecosystem | Deloitte US has been saved
Limited functionality available
By Rajesh Singh, managing director, Deloitte Consulting LLP
Cell and gene therapies (CGTs) have shown promise in their ability to cure disease rather than merely treat symptoms. CGT, however, is still in its infancy and biopharma companies typically need to synchronize multiple stakeholders and processes to ensure the therapies deliver on their clinical promises and meet patient expectations.
I recently participated in a digital workshop—in collaboration with London-based Hanson Wade—that looked at the steps involved in designing a patient-centric digital ecosystem for CGT. These living therapies are customized for each patient, and the ability to create a new therapy is dependent upon that patient. Moreover, the nature of a CGT product requires biopharma companies to collaborate with a variety of stakeholders including hospitals, contract manufacturing organizations, and couriers. CGT also involves multiple hand-off points, all of which need to be tracked.
John Lally, senior director of Commercial Innovation and Digital Strategy at Vertex Pharmaceuticals, was my co-presenter during this session. He drew a parallel between an orchestra and the many players involved in CGT. Each player in an orchestra, he explained, has a piece of sheet music to follow. The conductor of this orchestra (like the biopharma company) controls the score and is responsible for ensuring that individual players work together to achieve harmony. The score shows the conductor how all the pieces of music need to fit together to make music. This analogy helps to explain the different types of deliverables we create when planning for CGT.
Deloitte's 2020 report on CGT explains why developing a patient-centered value chain is a new competency that requires a whole new way of organizing and operating. Here are a few key considerations for the successful orchestration of cell and gene therapies:
The effectiveness of CGT might depend on how well biopharma companies collaborate with stakeholders to enable the patient journey. Using the components above to create a blueprint that is centered around the patient can help biopharma companies anticipate and overcome challenges.
Acknowledgement: Josh Fyffe, senior consultant, Deloitte Consulting LLP
This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor.
Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.
Return to the Health Forward home page to discover more insights from our leaders.